89BIO, INC. (ETNB): Price and Financial Metrics


89BIO, INC. (ETNB): $11.68

0.54 (+4.85%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ETNB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ETNB Stock Price Chart Interactive Chart >

Price chart for ETNB

ETNB Price/Volume Stats

Current price $11.68 52-week high $12.95
Prev. close $11.14 52-week low $2.00
Day low $10.73 Volume 1,065,072
Day high $11.74 Avg. volume 818,764
50-day MA $10.29 Dividend yield N/A
200-day MA $6.17 Market Cap 543.55M

89BIO, INC. (ETNB) Company Bio


89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.


ETNB Latest News Stream


Event/Time News Detail
Loading, please wait...

ETNB Latest Social Stream


Loading social stream, please wait...

View Full ETNB Social Stream

Latest ETNB News From Around the Web

Below are the latest news stories about 89BIO INC that investors may wish to consider to help them evaluate ETNB as an investment opportunity.

Blueprint Medicines' (BPMC) Aykavit sNDA Gets FDA Priority Tag

The FDA accepts and grants priority review to Blueprint Medicines' (BPMC) sNDA for the label expansion of Aykavit for indolent systemic mastocytosis.

Yahoo | January 24, 2023

With stock up 19%, Insiders of 89bio, Inc. (NASDAQ:ETNB) must be wishing they had bought more last year

Insiders who bought 89bio, Inc. ( NASDAQ:ETNB ) stock in the last 12 months were richly rewarded last week. The...

Yahoo | January 22, 2023

89bio Provides Business Update and Outlook for 2023

– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 – – Feedback from FDA supports advancement of Phase 3 program for pegozafermin in SHTG; plan to initiate first of two SHTG Phase 3 trials in the first half of 2023 – – Secured $100 million credit facility with K2 HealthVentures; pro forma cash of $188.4 million as of December 31, 2022 – SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focuse

Yahoo | January 4, 2023

Analysts Predicting A Spike In 89bio Inc. (NASDAQ: ETNB)?

89bio Inc. (NASDAQ:ETNB) price on Thursday, December 22, fall -1.37% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $11.55. A look at the stock’s price movement, the close in the last trading session was $11.71, moving within a range at $11.31 and $11.95. The beta value (5-Year … Analysts Predicting A Spike In 89bio Inc. (NASDAQ: ETNB)? Read More »

Stocks Register | December 23, 2022

89bio Inc. (ETNB) Rises From The Low: Could It Be A Catbird Seat?

89bio Inc. (NASDAQ:ETNB) concluded the trading at $10.20 on Wednesday, December 14 with a rise of 9.32% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $9.33 and 5Y monthly beta was reading 0.93 with its price kept floating in the range … 89bio Inc. (ETNB) Rises From The Low: Could It Be A Catbird Seat? Read More »

Stocks Register | December 15, 2022

Read More 'ETNB' Stories Here

ETNB Price Returns

1-mo -8.25%
3-mo 25.46%
6-mo 224.44%
1-year 98.30%
3-year -56.29%
5-year N/A
YTD -8.25%
2022 -2.60%
2021 -46.37%
2020 -7.30%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.75 seconds.